Investigational drug · Phase 3
HS-10380
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for SCHIZOPHRENIA 1 (Disorder).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "HS-10380"
First trial start
2024
May 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10380", any sponsor or status.
Conditions studied
As listed on its trial records.
- SCHIZOPHRENIA 1 (Disorder)
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10380" as an intervention, largest first.
- A Study to Evaluate the Long-term Safety of HS-10380 in Patients With SchizophreniaPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07759869 · 500 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 31, 2028
Drug: HS-10380 · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Beijing, China
- Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese AdultsPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07911787 · 476 participants (planned) · Start Nov 4, 2026 · Primary completion Jan 24, 2029
Drug: HS-10380; Aripiprazole and 1 more · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Shanghai, China
- A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute SchizophreniaPivotal-lookingCompleted
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07550387 · 363 participants · Start May 23, 2024 · Primary completion Jan 2, 2026
Drug: HS-10380 Low Dose; HS-10380 Medium dose and 3 more · For: SCHIZOPHRENIA 1 (Disorder)
Sites: Shanghai, China
- Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With SchizophreniaPivotal-lookingStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05964790 · 112 participants (planned) · Start Jul 30, 2023 · Primary completion Jun 30, 2024
Drug: HS-10380; Placebo · For: Schizophrenia
- A Study of HS-10380 in Chinese ParticipantsStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05480592 · 76 participants (planned) · Start Aug 1, 2022 · Primary completion Jun 30, 2023
Drug: HS-10380; Placebo · For: Schizophrenia
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.